Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + bevacizumab + pemetrexed + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ORIENT-31 refers to a therapeutic regimen consisting of the PD-1 inhibitor sintilimab, a bevacizumab biosimilar (IBI305), and platinum-based doublet chemotherapy (typically pemetrexed combined with cisplatin or carboplatin). This combination was pioneered by Innovent Biologics and evaluated in the ORIENT-31 Phase 3 trial for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed after EGFR tyrosine kinase inhibitor (TKI) therapy. The regimen aims to overcome resistance to TKIs by combining immune checkpoint blockade, anti-angiogenesis, and cytotoxic chemotherapy. The ORBIT study further explores this regimen in combination with stereotactic body radiotherapy (SBRT).
- Other names
- ORIENT-31 regimenORIENT31 regimenORIENT 31 regimensintilimab plus bevacizumab plus platinum-doublet chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on sintilimab + bevacizumab + pemetrexed + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + bevacizumab + pemetrexed + cisplatin + carboplatin.